May 2019 in “Journal of clinical oncology” Radiation therapy with chemotherapy can cause severe, long-lasting hair loss.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
January 2024 in “Current research in toxicology” Thallium is highly toxic, causing severe health issues, and Prussian blue is the best antidote.
1 citations
,
January 2008 Topical iodine can help regenerate human scar tissue quickly.
1 citations
,
June 2001 in “Annals of Internal Medicine” Troglitazone increases subcutaneous fat in lipodystrophy patients.
January 2024 in “Wiadomości Lekarskie” Thyroid disorders, especially autoimmune ones, are very common in the studied group.
4 citations
,
March 2017 in “Al-Mi’galaẗ al-sa'udiyaẗ lī-ulum al-ḥayaẗ” Leonuri Herba alkaloids may help treat hormone-induced enlarged prostate in rats.
8 citations
,
February 2019 in “Scientific Reports” Immunofluorescence tomography is a cost-effective method for creating detailed 3-D images of tissues.
June 2020 in “AACE clinical case reports” A woman's severe male hormone excess was caused by a small, hard-to-find ovarian tumor.
October 2016 in “Letters in Drug Design & Discovery” July 2024 in “Journal of Controlled Release” Nanostructured lipid carriers effectively deliver tofacitinib to hair follicles, reversing hair loss in alopecia areata.
January 2023 in “Bioorganičeskaâ himiâ” The new compound is a promising, less toxic alternative to finasteride for treating prostate issues.
1 citations
,
June 2021 in “Disease and Diagnosis” Hashimoto thyroiditis can unexpectedly change into Graves’ disease, so early diagnosis and treatment are important.
21 citations
,
July 2004 in “Apmis” Fluorescent proteins help visualize and understand tumor blood vessel growth.
23 citations
,
October 2012 in “ChemistryOpen” Probe detects finasteride with high selectivity and low detection limit.
3 citations
,
June 2016 in “Gynecological Endocrinology” Doctors used a special blood sampling technique to diagnose a woman's rare ovarian tumor that was producing male hormones.
4 citations
,
August 2011 in “The Lancet Oncology” Off-label drug use can be risky and requires careful consideration to ensure patient safety.
3 citations
,
January 2021 in “touchREVIEWS in Endocrinology” Surgery removed an ovarian tumor, improving her symptoms and normalizing testosterone levels.
1 citations
,
February 2002 in “Oncology Times” Intravenous arsenic is safe and effective for treating certain blood cancers.
13 citations
,
January 2001 in “Skin pharmacology and physiology” Micro-Imager® helps see how drugs spread in human skin.
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
July 2018 in “International Journal of Research in Dermatology” The patient was diagnosed with hypothyroidism and treated with medication and supplements.
11 citations
,
October 2011 in “Dermato-endocrinology” Many alopecia patients have undetected thyroid abnormalities that can be found through physical exams.
2 citations
,
January 1968 in “PubMed” Sulfur-containing radioprotectors can protect hair from X-ray damage if given before exposure but worsen damage if given after.
11 citations
,
June 2016 in “European Journal of Medicinal Chemistry” Compounds 6f and 6g effectively stop prostate cancer cell growth without harming healthy cells.
18 citations
,
October 2016 in “European Journal of Pharmaceutics and Biopharmaceutics” The drug was successfully released into hair follicles using nanocarriers.
7 citations
,
January 2025 in “Journal of Medicinal Chemistry” New itaconate prodrugs improve its absorption and effectiveness for treating inflammation.
67 citations
,
October 2005 in “Annals of Oncology” Fulvestrant is a well-tolerated new treatment for advanced breast cancer that may delay chemotherapy.
November 2020 in “Journal of The American Academy of Dermatology” Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
82 citations
,
February 1989 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism” A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.